VistaGen Therapeutics Inc. (VTGN) saw its loss narrow to $10.26 million, or $1.54 a share for the year ended Mar. 31, 2017. In the previous year period, the company reported a loss of $47.22 million, or $29.08 a share.

Revenues for the year were $1.25 million. The company has not recorded any revenues for the previous year.

Operating loss for the year was $10.25 million, compared with an operating loss of $17.85 million in the previous year.

"With a team of industry experts and a focused strategy in place, we have established a strong foundation and embarked on paths to achieve several key catalysts within the next 18 months. We anticipate our first catalyst within the next 9 months as the NIMH completes its AV-101 Phase 2 monotherapy study in MDD, a study being conducted and fully funded by the NIH. Additionally, we are working closely with the FDA and our Principal Investigator, Dr. Maurizio Fava of Harvard University Medical School, on our AV-101 Phase 2 adjunctive treatment study in MDD, which we anticipate will begin enrollment in the first quarter of 2018 and be completed by the end of 2018, with topline results available in the first quarter of 2019," commented Shawn Singh, chief executive officer of VistaGen.